285 related articles for article (PubMed ID: 20856931)
1. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.
Hatakeyama H; Cheng H; Wirth P; Counsell A; Marcrom SR; Wood CB; Pohlmann PR; Gilbert J; Murphy B; Yarbrough WG; Wheeler DL; Harari PM; Guo Y; Shyr Y; Slebos RJ; Chung CH
PLoS One; 2010 Sep; 5(9):e12702. PubMed ID: 20856931
[TBL] [Abstract][Full Text] [Related]
2. Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines.
Oshima G; Wennerberg J; Yamatodani T; Kjellén E; Mineta H; Johnsson A; Ekblad L
J Cancer Res Clin Oncol; 2012 Mar; 138(3):491-9. PubMed ID: 22193422
[TBL] [Abstract][Full Text] [Related]
3. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
[TBL] [Abstract][Full Text] [Related]
4. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
[TBL] [Abstract][Full Text] [Related]
5. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
6. miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling.
Wu Q; Zhao Y; Wang P
Biomed Pharmacother; 2018 Mar; 99():278-285. PubMed ID: 29353201
[TBL] [Abstract][Full Text] [Related]
7. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
[TBL] [Abstract][Full Text] [Related]
8. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
9. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
10. Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.
Oliveras-Ferraros C; Massaguer Vall-Llovera A; Carrion Salip D; Vazquez-Martin A; Cufí S; Queralt B; Martin-Castillo B; Brunet J; de Llorens R; Menendez JA
Invest New Drugs; 2012 Apr; 30(2):846-52. PubMed ID: 21161326
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
Ansell A; Jedlinski A; Johansson AC; Roberg K
J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
[TBL] [Abstract][Full Text] [Related]
12. Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma.
Fertig EJ; Ren Q; Cheng H; Hatakeyama H; Dicker AP; Rodeck U; Considine M; Ochs MF; Chung CH
BMC Genomics; 2012 May; 13():160. PubMed ID: 22549044
[TBL] [Abstract][Full Text] [Related]
13. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis.
Kumar B; Yadav A; Lang J; Teknos TN; Kumar P
PLoS One; 2012; 7(5):e37601. PubMed ID: 22629428
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells.
Johansson AC; Ansell A; Jerhammar F; Lindh MB; Grénman R; Munck-Wikland E; Östman A; Roberg K
Mol Cancer Res; 2012 Sep; 10(9):1158-68. PubMed ID: 22809838
[TBL] [Abstract][Full Text] [Related]
16. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
17. YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer.
Jerhammar F; Johansson AC; Ceder R; Welander J; Jansson A; Grafström RC; Söderkvist P; Roberg K
Oral Oncol; 2014 Sep; 50(9):832-9. PubMed ID: 24993889
[TBL] [Abstract][Full Text] [Related]
18. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U
Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686
[TBL] [Abstract][Full Text] [Related]
19. SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.
Ozawa H; Ranaweera RS; Izumchenko E; Makarev E; Zhavoronkov A; Fertig EJ; Howard JD; Markovic A; Bedi A; Ravi R; Perez J; Le QT; Kong CS; Jordan RC; Wang H; Kang H; Quon H; Sidransky D; Chung CH
Clin Cancer Res; 2017 Sep; 23(17):5162-5175. PubMed ID: 28522603
[No Abstract] [Full Text] [Related]
20. MicroRNA alterations in head and neck squamous cell carcinoma.
Chang SS; Jiang WW; Smith I; Poeta LM; Begum S; Glazer C; Shan S; Westra W; Sidransky D; Califano JA
Int J Cancer; 2008 Dec; 123(12):2791-7. PubMed ID: 18798260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
